Latest Trials Latest NewsFAQ

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Biological: Peptide Vaccine (PR1 Peptide)
Drug: Imatinib
Drug: Peginterferon alfa-2b
Drug: GM-CSF

First Posted Date: 2006-12-25

Last Posted Date: 2018-08-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00415857

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States

Treatment of Resectable Malignant Brain Tumors

Phase 4

Terminated

Conditions: Brain Tumor

Interventions: Device: GliaSite Radiation Therapy System

First Posted Date: 2006-12-25

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00415467

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

Phase 2

Terminated

Conditions: Leiomyosarcoma
Uterine Neoplasm

Interventions: Drug: Letrozole

First Posted Date: 2006-12-21

Last Posted Date: 2018-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00414076

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Acute Myelogenous Leukemia

Interventions: Drug: Decitabine
Drug: Valproic Acid

First Posted Date: 2006-12-21

Last Posted Date: 2019-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 153

Registration Number: NCT00414310

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Phase 2

Completed

Conditions: Acute Promyelocytic Leukemia

Interventions: Drug: All-Trans Retinoic Acid (ATRA)
Drug: Arsenic Trioxide (ATO)
Drug: Idarubicin
Drug: Gemtuzumab Ozogamicin

First Posted Date: 2006-12-19

Last Posted Date: 2019-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT00413166

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: 5-Azacytidine

First Posted Date: 2006-12-19

Last Posted Date: 2015-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00413478

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients

Phase 1

Completed

Conditions: Burkitt's Lymphoma
Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia

Interventions: Drug: Clofarabine
Drug: Cyclophosphamide

First Posted Date: 2006-12-18

Last Posted Date: 2013-03-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT00412243

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Smoking Status and Body Image in Oral Cancer Patients

Completed

Conditions: Oral Cavity Cancer

Interventions: Behavioral: Questionnaire
Behavioral: Interview

First Posted Date: 2006-12-18

Last Posted Date: 2016-01-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT00412490

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Phase 2

Recruiting

Conditions: Hairy Cell Leukemia
Recurrent Hairy Cell Leukemia

Interventions: Drug: Cladribine
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2006-12-18

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT00412594

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Palonosetron

First Posted Date: 2006-12-18

Last Posted Date: 2012-05-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00412425

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy